Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.37 USD
−52.37 M USD
0.00 USD
45.03 M
About Acumen Pharmaceuticals, Inc.
Sector
CEO
Daniel J. O'Connell
Headquarters
Charlottesville
Website
Founded
1996
FIGI
BBG0058YJ317
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ABOS is 1.85 USD — it has increased by 2.78% in the past 24 hours. Watch Acumen Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Acumen Pharmaceuticals, Inc. stocks are traded under the ticker ABOS.
ABOS stock has fallen by −11.48% compared to the previous week, the month change is a −23.55% fall, over the last year Acumen Pharmaceuticals, Inc. has showed a −41.27% decrease.
We've gathered analysts' opinions on Acumen Pharmaceuticals, Inc. future price: according to them, ABOS price has a max estimate of 15.00 USD and a min estimate of 10.00 USD. Watch ABOS chart and read a more detailed Acumen Pharmaceuticals, Inc. stock forecast: see what analysts think of Acumen Pharmaceuticals, Inc. and suggest that you do with its stocks.
ABOS reached its all-time high on Jul 1, 2021 with the price of 26.98 USD, and its all-time low was 1.72 USD and was reached on Dec 19, 2024. View more price dynamics on ABOS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ABOS stock is 6.29% volatile and has beta coefficient of 2.82. Track Acumen Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Acumen Pharmaceuticals, Inc. there?
Today Acumen Pharmaceuticals, Inc. has the market capitalization of 111.15 M, it has decreased by −10.09% over the last week.
Yes, you can track Acumen Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Acumen Pharmaceuticals, Inc. is going to release the next earnings report on Mar 31, 2025. Keep track of upcoming events with our Earnings Calendar.
ABOS earnings for the last quarter are −0.50 USD per share, whereas the estimation was −0.36 USD resulting in a −38.22% surprise. The estimated earnings for the next quarter are −0.49 USD per share. See more details about Acumen Pharmaceuticals, Inc. earnings.
Acumen Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ABOS net income for the last quarter is −29.77 M USD, while the quarter before that showed −20.54 M USD of net income which accounts for −44.93% change. Track more Acumen Pharmaceuticals, Inc. financial stats to get the full picture.
No, ABOS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 52.00 employees. See our rating of the largest employees — is Acumen Pharmaceuticals, Inc. on this list?
Like other stocks, ABOS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Acumen Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Acumen Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Acumen Pharmaceuticals, Inc. stock shows the strong sell signal. See more of Acumen Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.